ArticleJournal of ovarian research2021

Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression.

Jun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.